HETERO COMPOUND

摘要

It is intended to provide a useful compound as an active ingredient of a preventive and/or therapeutic agent for rejection in the transplantation of an organ, bone marrow, or tissue, an autoimmune disease or the like which has a n excellent S1P1 agonist effect. Because the compound of the invention has an S1P1 agonist effect, it is useful as an active ingredient of a therapeutic agent or a preventive agent for a disease caused by unfavorable lymphocytic infiltration, for example, an autoimmune disease such as graft rejection in the transplantation of an organ, bone marrow, or tissue or graft-versus-host disease, rheumatic arthritis, multiple sclerosis, systemic lupus erythematosus, nephrotic syndrome, encephalomeningitis, myasthenia gravis, pancreatitis, hepatitis, nephritis, diabetes, pulmonary disorder, asthma, atopic dermatitis, inflammatory bowel disease, atherosclerosis, or ischemia- reperfusion injury or an inflammatory disease, and further, a disease caused by the abnormal growth or accumulation of cells such as cancer or leukemia.< /SDOAB>